Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023

Tervaert, Jan Willem Cohen; Martı́nez-Lavı́n, Manuel; Jara, Luis J.; Halpert, Gilad; Watad, Abdulla; Amital, Howard; Shoenfeld, Yehuda

doi:10.1016/j.autrev.2023.103287

Cited by 48 publications

(50 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A third dose of the vaccine has been advocated to confer adequate immunization in GCA patients, many of them under methotrexate and glucocorticoid treatment which may results in lower neutralizing activity and cellular immune protection than healthy controls [ 40 ]. However, the inclusion of GCA among the potential conditions associated with the Autoimmune/inflammatory syndrome induced by adjuvants (ASIA), and, particularly, with post-covid-19 vaccination ASIA [ 41 , 42 ], should be also taken into account. Moreover, according to our results, the future vaccine policies must weigh the risk of severe COVID-19 against the risk of flare and, especially, of stroke in patients with GCA.…”

Section: Discussionmentioning

confidence: 99%

Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study

Moreno-Torres¹,

Soriano²,

Calderón-Parra³

et al. 2023

Autoimmunity Reviews

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study

Moreno-Torres¹,

Soriano²,

Calderón-Parra³

et al. 2023

Autoimmunity Reviews

View full text Add to dashboard Cite

“…123 BII specifically refers to symptoms associated with breast implants and appears to occur in <1% of patients with breast implants. 124 The attributed symptoms vary from rare and nonspecific 125 to rheumatic 126 and systemic complaints. 127 As a proof of concept, removal of breast implants without replacement has been reported to reverse the symptoms of BII in a subset of patients.…”

Section: Breast Implant Illness and Autoimmune/ Inflammatory Syndrome...mentioning

confidence: 99%

“…Patients are usually 30 to 50 years of age, and the mean onset of symptoms after breast implantation is 16 years. 124 The most common symptoms of BII include fatigue (~50%), brain fog (~25%), joint pain (~25%), and in about 20% of patients anxiety, hair loss, depression, skin rash, autoimmune diseases, systemic inflammation and/or weight problems. 131 McGuire et al 132 found in a controlled prospective study that patients with BII have higher levels of C reactive protein, serum IgG anti-Staphylococcus aureus, IL-17, IL-13, and IL-22 than patients with breast implants without BII.…”

Section: Clinical Featuresmentioning

confidence: 99%

“…Such adjuvants include aluminum salts used in vaccines, medical implants, and infectious agents that affect susceptible individuals 123 . BII specifically refers to symptoms associated with breast implants and appears to occur in <1% of patients with breast implants 124 . The attributed symptoms vary from rare and nonspecific 125 to rheumatic 126 and systemic complaints 127 .…”

Section: Breast Implant Illness and Autoimmune/inflammatory Syndrome ...mentioning

confidence: 99%

“…Patients are usually 30 to 50 years of age, and the mean onset of symptoms after breast implantation is 16 years 124 . The most common symptoms of BII include fatigue (~50%), brain fog (~25%), joint pain (~25%), and in about 20% of patients anxiety, hair loss, depression, skin rash, autoimmune diseases, systemic inflammation and/or weight problems 131 .…”

Section: Breast Implant Illness and Autoimmune/inflammatory Syndrome ...mentioning

confidence: 99%

See 2 more Smart Citations

The Spectrum of Non-neoplastic Changes Associated With Breast Implants

Marques-Piubelli,

Lyapichev,

FNU

et al. 2024

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma has been recognized as a distinct entity in the World Health Organization classification of hematolymphoid neoplasms. These neoplasms are causally related to textured implants that were used worldwide until recently. Consequently, there is an increased demand for processing periprosthetic capsules, adding new challenges for surgeons, clinicians, and pathologists. In the literature, the focus has been on breast implant-associated anaplastic large cell lymphoma; however, benign complications related to the placement of breast implants occur in up to 20% to 30% of patients. Imaging studies are helpful in assessing patients with breast implants for evidence of implant rupture, changes in tissues surrounding the implants, or regional lymphadenopathy related to breast implants, but pathologic examination is often required. In this review, we couple our experience with a review of the literature to describe a range of benign lesions associated with breast implants that can be associated with different clinical presentations or pathogenesis and that may require different diagnostic approaches. We illustrate the spectrum of the most common of these benign disorders, highlighting their clinical, imaging, gross, and microscopic features. Finally, we propose a systematic approach for the diagnosis and handling of breast implant specimens in general.

show abstract

Uplifting Antitumor Immunotherapy with Lymph‐Node‐Targeted and Ratio‐Controlled Codelivery of Tumor Cell Lysate and Adjuvant

Cui,

Sun,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Cancer vaccines provide a potential strategy to cure patients. Their clinical utilization and efficacy is, however, limited by incomplete coverage of tumor neoantigens and unspecific and restricted activation of dendritic cells (DCs). Tumor cell lysates (TCL) containing a broad spectrum of neoantigens, while are considered ideal in formulating personalized vaccines, induce generally poor antigen presentation and transient anti‐tumor immune response. Here, intelligent polymersomal nanovaccines (PNVs) that quantitatively co‐load, efficiently co‐deliver and responsively co‐release TCL and CpG adjuvant to lymph node (LN) DCs are developed to boost antigen presentation and to induce specific and robust anti‐tumor immunity. PNVs carrying CpG and OVA (CpG/OVA@PNV) markedly enhanced the maturation, antigen presentation and downstream T cell activation ability of BMDCs and induced strong systemic immune response after tail base injection. Remarkably, PNVs carrying CpG and TCL (CpG/TCL@PNV) cured 85% of B16‐F10 melanoma‐bearing mice and generated long‐lasting anti‐cancer immune memory at a low dose, protecting all cured mice from tumor re‐challenge. These LN‐directed PNVs being highly versatile and straightforward opens a new door for personalized cancer vaccines.This article is protected by copyright. All rights reserved

show abstract

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023

Cited by 48 publications

References 99 publications

Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study

Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study

The Spectrum of Non-neoplastic Changes Associated With Breast Implants

Uplifting Antitumor Immunotherapy with Lymph‐Node‐Targeted and Ratio‐Controlled Codelivery of Tumor Cell Lysate and Adjuvant

Contact Info

Product

Resources

About